vs
GREAT SOUTHERN BANCORP, INC.（GSBC）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
GREAT SOUTHERN BANCORP, INC.的季度营收约是RECURSION PHARMACEUTICALS, INC.的1.6倍（$56.4M vs $35.5M），GREAT SOUTHERN BANCORP, INC.净利率更高（28.9% vs -304.2%，领先333.1%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs -0.2%），GREAT SOUTHERN BANCORP, INC.自由现金流更多（$70.1M vs $-47.3M），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 4.5%）
该企业是美国的多元化银行金融机构，总部位于明尼苏达州明尼阿波利斯，在特拉华州注册。截至2025年，它是美国第五大银行，也是美国中西部规模最大的银行，被金融稳定委员会认定为具有系统重要性的金融机构，主营零售及企业银行业务、投资、抵押贷款等多元金融服务。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
GSBC vs RXRX — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $56.4M | $35.5M |
| 净利润 | $16.3M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | 34.5% | -304.8% |
| 净利率 | 28.9% | -304.2% |
| 营收同比 | -0.2% | 681.7% |
| 净利润同比 | 9.1% | 39.6% |
| 每股收益（稀释后） | $1.44 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $56.4M | $35.5M | ||
| Q3 25 | $57.8M | $5.2M | ||
| Q2 25 | $59.2M | $19.2M | ||
| Q1 25 | $55.9M | $14.7M | ||
| Q4 24 | $56.5M | $4.5M | ||
| Q3 24 | $55.0M | $26.1M | ||
| Q2 24 | $56.7M | $14.4M | ||
| Q1 24 | $51.6M | $13.8M |
| Q4 25 | $16.3M | $-108.1M | ||
| Q3 25 | $17.8M | $-162.3M | ||
| Q2 25 | $19.8M | $-171.9M | ||
| Q1 25 | $17.2M | $-202.5M | ||
| Q4 24 | $14.9M | $-178.9M | ||
| Q3 24 | $16.5M | $-95.8M | ||
| Q2 24 | $17.0M | $-97.5M | ||
| Q1 24 | $13.4M | $-91.4M |
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% | ||
| Q1 24 | — | 19.1% |
| Q4 25 | 34.5% | -304.8% | ||
| Q3 25 | 38.2% | -3327.6% | ||
| Q2 25 | 41.0% | -916.8% | ||
| Q1 25 | 38.4% | -1297.9% | ||
| Q4 24 | 31.8% | -4042.4% | ||
| Q3 24 | 36.6% | -377.1% | ||
| Q2 24 | 36.8% | -697.4% | ||
| Q1 24 | 32.1% | -698.4% |
| Q4 25 | 28.9% | -304.2% | ||
| Q3 25 | 30.7% | -3135.3% | ||
| Q2 25 | 33.4% | -894.2% | ||
| Q1 25 | 30.7% | -1373.3% | ||
| Q4 24 | 26.4% | -3935.5% | ||
| Q3 24 | 30.0% | -367.5% | ||
| Q2 24 | 30.0% | -676.6% | ||
| Q1 24 | 26.0% | -662.4% |
| Q4 25 | $1.44 | $-0.17 | ||
| Q3 25 | $1.56 | $-0.36 | ||
| Q2 25 | $1.72 | $-0.41 | ||
| Q1 25 | $1.47 | $-0.50 | ||
| Q4 24 | $1.27 | $-0.56 | ||
| Q3 24 | $1.41 | $-0.34 | ||
| Q2 24 | $1.45 | $-0.40 | ||
| Q1 24 | $1.13 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $189.6M | $743.3M |
| 总债务越低越好 | — | $9.6M |
| 股东权益账面价值 | $636.1M | $1.1B |
| 总资产 | $5.6B | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
| Q4 25 | $189.6M | $743.3M | ||
| Q3 25 | $196.2M | $659.8M | ||
| Q2 25 | $245.9M | $525.1M | ||
| Q1 25 | $217.2M | $500.5M | ||
| Q4 24 | $195.8M | $594.4M | ||
| Q3 24 | $208.4M | $427.6M | ||
| Q2 24 | $186.5M | $474.3M | ||
| Q1 24 | $171.4M | $296.3M |
| Q4 25 | — | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M | ||
| Q1 24 | — | — |
| Q4 25 | $636.1M | $1.1B | ||
| Q3 25 | $632.9M | $1.0B | ||
| Q2 25 | $622.4M | $919.1M | ||
| Q1 25 | $613.3M | $933.9M | ||
| Q4 24 | $599.6M | $1.0B | ||
| Q3 24 | $612.1M | $524.6M | ||
| Q2 24 | $568.8M | $584.4M | ||
| Q1 24 | $565.2M | $401.2M |
| Q4 25 | $5.6B | $1.5B | ||
| Q3 25 | $5.7B | $1.4B | ||
| Q2 25 | $5.9B | $1.3B | ||
| Q1 25 | $6.0B | $1.3B | ||
| Q4 24 | $6.0B | $1.4B | ||
| Q3 24 | $6.0B | $726.5M | ||
| Q2 24 | $6.0B | $775.9M | ||
| Q1 24 | $5.8B | $557.8M |
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $81.5M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $70.1M | $-47.3M |
| 自由现金流率自由现金流/营收 | 124.3% | -133.1% |
| 资本支出强度资本支出/营收 | 20.3% | 3.5% |
| 现金转化率经营现金流/净利润 | 5.01× | — |
| 过去12个月自由现金流最近4个季度 | $121.9M | $-378.3M |
8季度趋势，按日历期对齐
| Q4 25 | $81.5M | $-46.1M | ||
| Q3 25 | $5.6M | $-117.4M | ||
| Q2 25 | $39.3M | $-76.4M | ||
| Q1 25 | $15.0M | $-132.0M | ||
| Q4 24 | $44.1M | $-115.4M | ||
| Q3 24 | $17.7M | $-59.2M | ||
| Q2 24 | $43.5M | $-82.2M | ||
| Q1 24 | $-26.9M | $-102.3M |
| Q4 25 | $70.1M | $-47.3M | ||
| Q3 25 | $3.9M | $-117.6M | ||
| Q2 25 | $34.9M | $-79.6M | ||
| Q1 25 | $13.1M | $-133.8M | ||
| Q4 24 | $39.1M | $-116.7M | ||
| Q3 24 | $16.5M | $-63.8M | ||
| Q2 24 | $42.0M | $-83.4M | ||
| Q1 24 | $-27.7M | $-109.0M |
| Q4 25 | 124.3% | -133.1% | ||
| Q3 25 | 6.7% | -2272.5% | ||
| Q2 25 | 59.0% | -413.9% | ||
| Q1 25 | 23.4% | -907.4% | ||
| Q4 24 | 69.3% | -2567.7% | ||
| Q3 24 | 30.1% | -244.6% | ||
| Q2 24 | 74.1% | -578.5% | ||
| Q1 24 | -53.7% | -789.9% |
| Q4 25 | 20.3% | 3.5% | ||
| Q3 25 | 3.0% | 4.7% | ||
| Q2 25 | 7.4% | 16.4% | ||
| Q1 25 | 3.5% | 12.4% | ||
| Q4 24 | 8.7% | 28.6% | ||
| Q3 24 | 2.1% | 17.5% | ||
| Q2 24 | 2.7% | 8.2% | ||
| Q1 24 | 1.6% | 48.2% |
| Q4 25 | 5.01× | — | ||
| Q3 25 | 0.31× | — | ||
| Q2 25 | 1.99× | — | ||
| Q1 25 | 0.87× | — | ||
| Q4 24 | 2.95× | — | ||
| Q3 24 | 1.07× | — | ||
| Q2 24 | 2.56× | — | ||
| Q1 24 | -2.01× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
